Barbara Waßmann

4.4k total citations · 1 hit paper
48 papers, 2.9k citations indexed

About

Barbara Waßmann is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Barbara Waßmann has authored 48 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Hematology, 33 papers in Public Health, Environmental and Occupational Health and 24 papers in Genetics. Recurrent topics in Barbara Waßmann's work include Chronic Myeloid Leukemia Treatments (40 papers), Acute Lymphoblastic Leukemia research (33 papers) and Chronic Lymphocytic Leukemia Research (23 papers). Barbara Waßmann is often cited by papers focused on Chronic Myeloid Leukemia Treatments (40 papers), Acute Lymphoblastic Leukemia research (33 papers) and Chronic Lymphocytic Leukemia Research (23 papers). Barbara Waßmann collaborates with scholars based in Germany, United States and United Kingdom. Barbara Waßmann's co-authors include Oliver G. Ottmann, Dieter Hoelzer, Lydia Wunderle, Andreas Hochhaus, Roman Pfeifer, Anja Binckebanck, Maher Albitar, Leila Alland, Hagop M. Kantarjian and Harald Gschaidmeier and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Barbara Waßmann

47 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

2006 970 citations Hagop M. Kantarjian, Francis J. Giles et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara Waßmann Germany	23	2.3k	1.2k	1.1k	925	534	48	2.9k
Giovanna Rege‐Cambrin Italy	21	1.4k 0.6×	669 0.6×	893 0.8×	352 0.4×	293 0.5×	70	2.0k
BD Clarkson United States	25	2.2k 1.0×	632 0.5×	1.7k 1.5×	764 0.8×	521 1.0×	57	3.2k
Stefania Paolini Italy	20	1.3k 0.6×	644 0.6×	574 0.5×	315 0.3×	430 0.8×	88	1.9k
Mario Sessarego Italy	28	1.8k 0.8×	465 0.4×	882 0.8×	242 0.3×	387 0.7×	122	2.3k
Nicoletta Testoni Italy	35	3.7k 1.6×	676 0.6×	1.9k 1.7×	1.0k 1.1×	744 1.4×	187	4.4k
Laurence Legros France	30	3.6k 1.6×	403 0.3×	2.7k 2.4×	1.5k 1.6×	681 1.3×	126	4.1k
Carlo Finelli Italy	28	3.2k 1.4×	434 0.4×	1.7k 1.5×	242 0.3×	315 0.6×	108	4.1k
G. Alimena Italy	15	1.3k 0.5×	291 0.2×	832 0.7×	409 0.4×	305 0.6×	31	1.6k
A Schattenberg Netherlands	26	3.0k 1.3×	536 0.5×	629 0.6×	145 0.2×	1.2k 2.2×	77	4.0k
Z Arlin United States	27	1.7k 0.7×	766 0.7×	820 0.7×	149 0.2×	766 1.4×	71	2.8k

Countries citing papers authored by Barbara Waßmann

Since Specialization

Citations

This map shows the geographic impact of Barbara Waßmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Waßmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Waßmann more than expected).

Fields of papers citing papers by Barbara Waßmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Waßmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Waßmann. The network helps show where Barbara Waßmann may publish in the future.

Co-authorship network of co-authors of Barbara Waßmann

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Waßmann. A scholar is included among the top collaborators of Barbara Waßmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Waßmann. Barbara Waßmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wolf, Timo, Volker Rickerts, Schlomo Staszewski, et al.. (2007). First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe Aplastic Anemia. Haematologica. 92(4). e56–e58. 24 indexed citations

Waßmann, Barbara. (2007). Imatinib in Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia. Drugs. 67(17). 2655–2656. 1 indexed citations

Ottmann, Oliver G., Barbara Waßmann, Roman Pfeifer, et al.. (2007). Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL). Cancer. 109(10). 2068–2076. 151 indexed citations

Waßmann, Barbara. (2006). Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood. 108(5). 1469–1477. 239 indexed citations

Kantarjian, Hagop M., Francis J. Giles, Lydia Wunderle, et al.. (2006). Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL. New England Journal of Medicine. 354(24). 2542–2551. 970 indexed citations breakdown →

Bug, Gesine, Markus Ritter, Barbara Waßmann, et al.. (2005). Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia. Cancer. 104(12). 2717–2725. 154 indexed citations

Mousset, Sabine, Stella Hermann, Stefan Klein, et al.. (2005). Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Annals of Hematology. 84(11). 734–741. 73 indexed citations

Ottmann, Oliver G. & Barbara Waßmann. (2005). Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Hematology. 2005(1). 118–122. 49 indexed citations

Bruck, Patrick T., et al.. (2004). Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms. Leukemia Research. 28(11). 1153–1157. 8 indexed citations

10.

Waßmann, Barbara, Urban Scheuring, Christian Thiede, et al.. (2003). Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation. Bone Marrow Transplantation. 31(7). 611–614. 6 indexed citations

11.

Scheuring, Urban, Roman Pfeifer, Barbara Waßmann, et al.. (2003). Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. Leukemia. 17(9). 1700–1706. 29 indexed citations

12.

Waßmann, Barbara, Urban Scheuring, Anja Binckebanck, et al.. (2003). A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55�years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10). Annals of Hematology. 82(11). 716–720. 18 indexed citations

13.

Olavarría, Eduardo, Oliver G. Ottmann, Michael W. Deininger, et al.. (2003). Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia. 17(9). 1707–1712. 80 indexed citations

14.

Waßmann, Barbara, Urban Scheuring, Roman Pfeifer, et al.. (2003). Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia. 17(10). 1919–1924. 27 indexed citations

15.

Waßmann, Barbara, Roman Pfeifer, Urban Scheuring, et al.. (2003). Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. Blood. 103(4). 1495–1498. 39 indexed citations

16.

Ottmann, Oliver G. & Barbara Waßmann. (2002). Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts. Best Practice & Research Clinical Haematology. 15(4). 757–769. 16 indexed citations

17.

Waßmann, Barbara, Urban Scheuring, Roman Pfeifer, et al.. (2001). Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. Bone Marrow Transplantation. 28(7). 721–724. 19 indexed citations

18.

Hermann, Stella, Stefan Klein, Volkmar Jacobi, et al.. (2001). Older patients with high‐risk fungal infections can be successfully allografted using non‐myeloablative conditioning in combination with intensified supportive care regimens. British Journal of Haematology. 113(2). 446–454. 21 indexed citations

19.

Seipelt, G., W.-K. Hofmann, Barbara Waßmann, et al.. (1998). Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin. Annals of Hematology. 76(3-4). 145–151. 8 indexed citations

20.

Hebart, Holger, Arne Schröder, Jürgen Löffler, et al.. (1997). Cytomegalovirus Monitoring by Polymerase Chain Reaction of Whole Blood Samples from Patients Undergoing Autologous Bone Marrow or Peripheral Blood Progenitor Cell Transplantation. The Journal of Infectious Diseases. 175(6). 1490–1493. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact